Patent · US Active

Biomarkers for diabetes therapy

US12139761B2 · kind B2 · utility

0Cited by

0References

14Claims

0Family size

Assignees

Katholieke Universiteit Leuven · BE
UNIVERSITÀ DI SIENA · IT

Inventors

Constantia Gysemans · Heikant, BE
Chantal Mathieu · Buizingen, BE
Francesco Dotta · Roma, IT
Guido Sebastiani · Siena, IT
Giuliana Ventriglia · Caserta, IT

Key dates

Filing date	Mar 29, 2019
Grant date	Nov 12, 2024
Priority date	—
Expiry date	Mar 2, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/178
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The invention relates to an in-vitro method for identifying a diabetic patient as responder or non-responder to a treatment of Proinsulin, Interleukin 10 and anti-CD3, based on the expression level of at least 1 microRNA, selected from the group consisting of miR-365, miR-34a, miR-193b and miR-125a, in a sample from the diabetic patient prior to said treatment.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.